Who is sponsoring NCT00779129?

NCT00779129 is sponsored by Merck Sharp & Dohme LLC.

What condition does NCT00779129 study?

NCT00779129 studies Breast Neoplasm.

What drugs are being tested in NCT00779129?

Interventions: Pegylated Lyposomal Doxorubicin, Cyclophosphamide.

What is the status of NCT00779129?

NCT00779129 is currently COMPLETED.

Last reviewed 2015-09-29 · How we verify

Phase II Trial of Caelyx and Cyclophosphamide in Metastatic Breast Cancer

NCT00779129 Phase 2 COMPLETED

Women with metastatic breast cancer are usually treated with anthracyclines (ie, doxorubicin or epirubicin) but cardiac toxicity limits their use. The aim of this study is to evaluate the safety and efficacy of Caelyx in combination with cyclophosphamide in women with metastatic breast cancer who have received adjuvant anthracyclines with or without a taxane.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 2
Status	COMPLETED
Enrolment	70
Start date	2003-03
Completion	2007-08

Conditions

Breast Neoplasm

Interventions

Pegylated Lyposomal Doxorubicin
Cyclophosphamide

Primary outcomes

Time to response; Duration of response; Time to progression; Survival — With complete or partial response, subjects will be re-evaluated 4 weeks later to confirm the initial observation; Follow-up for a minimum of one year for survival.